Concept Medical Group, a global leader in drug-eluting technologies, has been awarded the prestigious Times Healthcare ...

LONDON, England—While it’s not clear sirolimus-based devices will ever overtake the old workhorse paclitaxel, data from several studies presented here at the 2025 Charing Cross International Symposium ...

Orchestra BioMed's AVIM earns FDA breakthrough designation, sparking investor optimism. Click here to read why OBIO stock is ...

Patients were treated with pexidartinib 1000 mg and sirolimus 2 mg orally daily. The primary end point was progression-free survival (PFS). Secondary end points included objective response, safety ...

Orchestra BioMed Holdings, Inc.’s OBIO share price has surged by 19.92%, which has investors questioning if this is right ...

PBI-Gordon Companies, Inc., an organization that inspires innovations for green spaces, pets, and people, announces the strategic acquisition of TriviumVet®, a leading research and development company ...

Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug-eluting stent (DES) and the efficacy and cost of using DESs versus bare-metal stents are discussed.

DelveInsight’s, "Neurofibrosarcoma Pipeline Insight 2025,” report provides comprehensive insights about 15+ companies and 15+ ...

New designation follows the U.S. Food and Drug Administration (FDA) Orphan Drug Designation for eRapa in FAP granted in 2019 Company nears start of Registrational Phase 3 study targeted at an ...

Furthermore, it elutes a relatively high dose of Sirolimus over several months, leading to excellent long-term outcomes, all without the need for a permanent implant," stated Prof. Holden.

Secured ten new fully-issued patents related to hypertension treatment during last 12 months, bringing global issued patent estate total ...